Your browser doesn't support javascript.
Decidual stromal cell therapy for generalized lymphadenopathy as a special clinical manifestation of COVID-19 infection: A case report.
Pirsalehi, Ali; Soleimani, Masoud; Hajifathali, Abbas; Sadeghi, Behnam; Farhadihosseinabadi, Behrouz; Akhlaghi, Sedigheh Sadat; Roshandel, Elham.
  • Pirsalehi A; Department of Internal Medicine School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.
  • Soleimani M; Hematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.
  • Hajifathali A; Hematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.
  • Sadeghi B; Translational Cell Therapy Research (TCR) Department of Clinical Science, Intervention and Technology CLINTEC Karolinska Instituted Huddinge Sweden.
  • Farhadihosseinabadi B; Hematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.
  • Akhlaghi SS; Department of Internal Medicine School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.
  • Roshandel E; Hematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.
Clin Case Rep ; 10(5): e05851, 2022 May.
Article in English | MEDLINE | ID: covidwho-1913763
ABSTRACT
We are going through the greatest global health crisis of the last decades, the coronavirus disease 2019 (COVID-19) pandemic. It may cause morbidity and mortality in some cases, and there is no therapeutic approach with reproducible and favorable outcomes. As clinical manifestations differ from patient to patient, any report regarding clinical symptoms has been beneficial for early detection and treatment. Due to the immunomodulatory effect of mesenchymal stem cells (MSCs), MSCs-based therapy has been approved to be one of the therapeutic strategies for COVID-19 management. For the first time in the literature, we reported generalized lymphadenopathy with fever and no sign of respiratory distress in a 16-year-old patient with confirmed COVID-19 infection as the main clinical signs. We also introduce decidual stromal cells as a potential immunomodulatory treatment for COVID-19-infected patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Language: English Journal: Clin Case Rep Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Language: English Journal: Clin Case Rep Year: 2022 Document Type: Article